Choose a language and wait for the translated text.
The FDA has approved two Jazz Pharmaceuticals regimens containing Ziihera for the first-line treatment of adults with unresectable, locally advanced or metastatic HER2-positive GEA.
Jazz secures FDA approval for Ziihera in advanced HER2+ GEA | PharmaVoice
